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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The collection of exhaled breath condensate (EBC) is a noninvasive
method that can be used to monitor the inflammatory status of patients with chronic airway
diseases. We aimed to study differences in cytokine expression between patients with exacer-
bations of chronic obstructive pulmonary disease (COPD) and patients with asthma attacks.
Methods: Using a custom-made device and methods based on American Thoracic Society
(ATS)/European Respiratory Society (ERS) recommendations, EBC samples were collected from
nine COPD patients, 12 asthma patients and 10 healthy individuals. Cytokine concentrations in
serum and EBC were measured via commercial ELISA kits.
Results: Of four cytokines measured in EBC [interleukin-8 (IL-8), IL-17, IL-4 and tumor necrosis
factor-a (TNF-a)], only IL-8 was significantly higher in COPD than in asthma patients (5.27 0.18
vs. 4.36  0.34 pg/mL, pZ 0.001). Moreover, COPD patients had higher serum IL-8 than asthma
patients (10.57  0.55 vs. 5.15  0.24 pg/mL, p < 0.001). No significant correlation between
serum and EBC cytokine concentrations was observed in each subgroup of patients.of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Number 250,
.
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IL-8 in serum and exhaled breath condensate 909Conclusion: Compared with patients with asthma attacks, patients with exacerbated COPD had
increased IL-8 expression in both serum and EBC. These results suggest that IL-8 may be more
important in airway and systemic inflammation in COPD exacerbations than in asthma attacks.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
airway inflammatory disease, characterized by irreversible
airflow limitation that increases progressively during the
natural course of the disease. Patients with COPD may
develop periods of exacerbated symptoms during their life,
and these symptoms are thought to be related to acute
infection.1 Recent studies indicated that recurrent exac-
erbation of COPD contributes to disease progression and
a poor prognosis.2,3 There is a lack of information about the
inflammatory mechanisms involved in exacerbations of
COPD. It is therefore important to investigate inflammatory
changes in patients with exacerbated COPD.
Exhaled breath condensate (EBC), formed through
a condensing device, is a noninvasive method to analyze
inflammatory biomarkers in patients with chronic pulmo-
nary disease. Increased leukotriene B4 and 8-isoprostane in
EBC of patients with exacerbated COPD has been reported
in a previous study.4 Increased interleukin-4 (IL-4) was
found in EBC from children with asthma, and this correlated
with the pathophysiologic characteristics of asthma.5
Although the methods used for EBC collection and anal-
ysis vary widely, there is considerable evidence to support
the use of EBC biomarkers for monitoring disease activity
and the response to pharmacological intervention.6,7
The involving immunological mechanism and associated
inflammatory mediators between asthma and COPD are
different. By secreting IL-4 and other cytokines, Th2 cells
play an important role in allergic airway inflammation in
asthma. IL-8, a chemokine of neutrophils, is correlated with
the extent of neutrophilic inflammation and disease
severity in COPD.8,9 Through analysis of induced sputum,
TNF-a is also considered to be important in inflammation of
COPD.8 IL-17, a proinflammatory cytokine mainly produced
by Th17 cells, is thought to induce and sustain the
neutrophil-mediated inflammatory response.10 Although
increased IL-17 concentrations have been reported in the
sputum of asthmatic patients,11 little is known about the
role of IL-17 in asthma or COPD.
Through measuring these cytokines in serum and EBC in
patients with exacerbated COPD and in patients with
asthma attacks, the goal of the present study is to char-
acterize the difference of the inflammatory cytokine
pattern between COPD exacerbations and asthma attacks.Methods
Participants and protocol
This study enrolled nine patients with acute exacerbations
of COPD and 12 patients with acute asthma attacks from
Chung-Shan Medical University Hospital. Another 10 healthyvolunteers were recruited from the medical staff and
served as a control group. The patients with exacerbated
COPD were required to have symptoms that fulfilled the
presentation defined by the guidelines from the Global
Initiative for Chronic Obstructive Lung Disease.1 The defi-
nition of acute asthma attack was according to the guide-
lines from the Global Initiative for Asthma.12 The healthy
participants had no history of smoking, no chronic under-
lying diseases, no recent upper airway infection and no
chronic respiratory symptoms (e.g., chronic cough,
productive cough, wheezing, etc.).
Patients with exacerbated COPD received both antibi-
otic treatment (oral or intravenous amoxicillin/clavulanic
acid for 3e5 days) and systemic steroids during admission,
but patients with asthma attacks received systemic
steroids only. All patients and healthy volunteers
completed a detailed questionnaire on their personal
medical history. We excluded patients with concomitant
pneumonia, patients with severe respiratory distress,
patients with severe hypoxemia and patients with an
unstable hemodynamic status. The protocol was approved
by the Institutional Review Board of the hospital, and
written informed consent was obtained from all
participants.Collection of exhaled breath condensate
EBC was collected with a custom-made condensing device,
and the collection time was 10 minutes when participants
were breathing at their tidal volume. The design of the
condensing device and collection methods were based on
recommendations by the American Thoracic Society/Euro-
pean Respiratory Society task force on EBC.13 The details of
the custom-made EBC collecting device are illustrated in
Fig. 1. It consisted of a Liebig condenser, a pump that
recycled cold water, a glass tube connector, a saliva trap
and two one-way valves. The condenser and its inner
surface were made of glass. Ice cold water (4C) was used
for cooling the condenser. The two one-way vales pre-
vented the patient from inhaling cold air that had passed
through the condenser during inspiration. The saliva trap
was designed to avoid saliva contamination during EBC
collection. There was no resistor or filter between the
participants and the condenser. Nose clips were not used
during EBC sampling, due to possible discomfort in patients
with obstructive airway diseases. The EBC collections were
done on Day 1 or Day 2 after hospitalization for patients
with exacerbated COPD or asthma attacks. To prevent the
influence of smoking on cytokine levels, patients who
smoked were advised to refrain from smoking for at least 12
hours before EBC collection. The EBC samples were stored
in 1.5 mL microcentrifuge tubes and frozen at 70C
immediately until further assay.
Figure 1 Schematic diagram of exhaled breath condensate (EBC) collecting device.
Table 1 Demographic data of all participants.
COPD
(n Z 9)
Asthma
(n Z 12)
Control
(n Z 10)
p
Age (y) 72  4.7 48  8.5 44  8.5 0.002
Females/
males
0/9 7/5 5/5 0.019
Weight (kg) 60  7 63  7 66  4 0.422
Height (cm) 164  3.9 162  5.5 165  4.7 0.931
FEV1/FVC
ratio
0.62  0.10 0.64  0.07 d 0.651
FEV1 (L) 1.29  0.52 1.58  0.55 d 0.356
FVC (L) 2.16  0.63 2.53  0.82 d 0.337
EBC volume
(mL)
703  213 742  230 1343  442 0.145
Smoking history 0.001
Non-
smokers
0 7 10
Smokers 9 5 0
COPD: patients with exacerbated COPD.
Asthma: patients with asthma attacks.
Control: healthy individuals.
COPDZ chronic obstructive pulmonary disease; EBCZ exhaled
breath condensate; FEV1 Z forced expiratory volume in 1
second; FVC Z forced vital capacity.
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Blood samples from patients with exacerbated COPD and
asthma attacks were drawn at the time when patients
completed EBC collections, clotted at 4C for 60 minutes
and then centrifuged for 30 minutes at 3000 rpm. Serum
samples were frozen at 70C immediately until further
assay.
Measurement of cytokine levels
The serum and EBC concentrations of IL-8, IL-17, IL-4, and
TNF-a were determined using commercially quantitative
enzyme-linked immunosorbent assay (ELISA) kits (eBio-
science, San Diego, CA) according to the manufacturer’s
instructions. However, there were a few deviations from
the manufacturer’s instructions in order to increase the
sensitivity of the assays. Processes including coating with
capture antibodies, blocking, incubation of samples, and
reaction with detecting antibodies, were performed at 4C,
and the reaction time was prolonged to 8 hours for
enhancing the assay sensitivity.
Intrasubject reproducibility of measurement was
assessed by collection of EBC in three healthy participants
and comparison of EBC cytokine concentrations within the
same individual. EBC samples were collected consecutively
three times in each healthy participant on the same day.
The cytokine concentrations in these samples were deter-
mined via the same ELISA plates. The average intrasubject
coefficients of variation were 6.6% and 7.5% for IL-8 and
TNF-a measurement, respectively.
Statistical analysis
Demographic and clinical data are expressed as the
mean  SD, and cytokine data as the mean  SEM. A Mann-
Whitney U-test and a Kruskal-Wallis test were used to
compare values among different groups. Correlations
between serum and EBC cytokine concentrations weredetermined using Spearman’s rank correlation test. A p
value <0.05 was considered significant. All analyses were
performed using the SPSS Rel. 12.0 statistical package (SPSS
Inc., Chicago, IL, USA).Results
Patient characteristics
The demographic data, lung function and volume of EBC
collected from all participants are shown in Table 1.
Compared with the exacerbated COPD patients, patients
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(p Z 0.002) and had a higher ratio of females to males
(p Z 0.019). The smoking status between these three
groups was significantly different. No significant differences
were found between the COPD and asthma patients in
forced expiratory volume in 1 second (FEV1)/forced vital
capacity (FVC) ratio, FEV1, FVC, collected EBC volume
(703  213 vs. 742  230 mL), body weight and height.
Cytokine concentrations in EBC
EBC measurements of IL-8 and IL-17 were performed in
patients with exacerbated COPD, patients with asthma
attacks and healthy participants. Because the EBC volume
was not sufficient in several patients’ samples, IL-4 was
measured only in patients with asthma attacks and healthy
participants, and TNF-a was measured only in patients with
exacerbated COPD and healthy participants.
The EBC IL-8 concentrations were significantly higher in
patients with exacerbated COPD than in patients with
asthma attacks (5.27  0.18 vs. 4.36  0.34 pg/mL,
pZ 0.001) (Fig. 2A). Patients with asthma attacks also had
lower EBC IL-8 concentrations than healthy individuals
(4.36  0.34 vs. 4.90  0.05 pg/mL, pZ 0.001). There was
no significant difference in EBC IL-8 expression betweenFigure 2 (A) Interleukin (IL)-8; (B) IL-17; (C) IL-4; and (D) tum
condensate (EBC) from patients with exacerbated chronic obstruc
asthma attack (Asthma: n Z 10e12), and healthy individuals (Conpatients with exacerbated COPD and healthy individuals
(p Z 0.061). The EBC IL-17 concentrations were not
significantly different among patients with exacerbated
COPD, patients with asthma attacks and healthy individuals
(0.90  0.27 vs. 0.50  0.12 vs. 0.54  0.15 pg/mL,
respectively) (Fig. 2B). The EBC IL-4 concentrations were
not significantly different between patients with asthma
attacks and healthy individuals (0.33  0.03 vs.
0.02  0.02 pg/mL) (Fig. 2C). The EBC TNF-a concentra-
tions were not significantly different between patients with
exacerbated COPD and healthy individuals (0.35  0.05 vs.
0.21  0.04 pg/mL) (Fig. 2D).
Serum cytokine concentrations
Because serum sampling was not done in healthy partici-
pants, serum measurements of IL-8 and IL-17 were per-
formed in patients with exacerbated COPD and patients
with asthma attacks. For matching serum data with EBC
data and economical concern, serum IL-4 was measured
only in patients with asthma attacks. The serum TNF-a was
measured only in patients with exacerbated COPD.
The serum IL-8 concentrations were also significantly
higher in patients with exacerbated COPD than in patients
with asthma attacks (10.57  0.55 vs. 5.15  0.24 pg/mL,or necrosis factor (TNF)-a concentrations in exhaled breath
tive pulmonary disease (COPD) (COPD: n Z 9), patients with
trol: n Z 10). Values are presented as mean  SEM.
Figure 3 Serum concentrations of (A) interleukin (IL)-8; and (B) IL-17 from patients with exacerbated chronic obstructive
pulmonary disease (COPD) (COPD: n Z 9) and from patients with asthma attacks (Asthma: n Z 11e12). Values are presented as
mean  SEM.
912 H.-C. Liu et al.p < 0.001) (Fig. 3A). The serum IL-17 concentrations were
not significantly different between patients with exacer-
bated COPD and patients with asthma attacks (5.61  2.02
vs. 3.31  0.90 pg/mL) (Fig. 3B). The values of serum IL-4
concentrations were 0.81  0.17 pg/mL in patients with
asthma attacks, and the values of serum TNF-a concentra-
tions were 3.16  0.77 pg/mL in patients with exacerbated
COPD.
Relationship between serum and EBC cytokine
levels
A correlation analysis was performed to determine the
relationship between serum and EBC cytokine levels in each
subgroup of patients (Table 2). There was no significant
correlation between serum and EBC levels of IL-8, IL-17, IL-
4 or TNF-a.
Discussion
We have shown that IL-8 concentrations were increased in
both serum and EBC from patients with exacerbated COPD,
when compared with patients with asthma attacks.
Neutrophils are considered to play a key role in the
pathogenesis of COPD and they are increased in the airwaysTable 2 Correlations of individual cytokine concentra-
tions between serum and exhaled breath condensate in
subgroup of patients.
Cytokine Correlation of serum and EBC
COPD Asthma
IL-8 R Z 0.085, p Z 0.828 R Z 0.54, p Z 0.07
IL-17 R Z 0.305, p Z 0.425 R Z 0.09, p Z 0.793
IL-4 R Z 0.114, p Z 0.753
TNF-a R Z 0.06, p Z 0.879
COPD Z chronic obstructive pulmonary disease; IL-
8Z interleukin-8; IL-17Z interleukin-17; IL-4Z interleukin-4;
TNF-a Z tumor necrosis factor-a.of smokers and patients with COPD.14,15 Exacerbation of
COPD is thought to be associated with further amplification
of inflammatory responses in the airways. Increased
neutrophil influx and concomitant IL-8 elevation were
observed in bronchoalveolar lavage (BAL) fluid of patients
with exacerbated COPD.16 In addition to leukotriene B4, IL-
8 is another important neutrophil chemoattractant in
COPD.17 A study by Keatings et al,8 showed significant
increases in neutrophils and IL-8 in induced sputum from
COPD patients compared with healthy individuals and
asthmatic patients. In our study, EBC IL-8 concentration
was higher in patients with exacerbated COPD than in
patients with asthma attacks, suggesting that neutrophil-
mediated airway inflammation is more dominant in COPD
exacerbation than asthma attacks.
A previous study showed that the sputum IL-8 concen-
tration in COPD patients rose from 69.8  26.1 ng/mL at
baseline to 127.3  46.2 ng/mL at the time of exacerba-
tion.18 Another study enrolled 25 COPD patients and
showed that the mean concentration of IL-8 in BAL fluid was
0.104 ng/mL.19 In our study, the mean EBC IL-8 concen-
tration in patients with exacerbated COPD was 5.27 pg/mL.
Therefore, the amount of cytokines in EBC is much lower
than that in BAL fluids or induced sputum. It was hypoth-
esized that the aerosolized protein from the airway lining
fluid was trapped in EBC during the process of condensation
of water vapor in exhaled air. However, the mechanisms
and site of EBC particle formation are not clearly under-
stood.13 A study showed that there is no significant corre-
lation between inflammatory mediator concentration in the
soluble phase of sputum and EBC.6 Jackson et al20 also
found that biomarkers in EBC and BAL did not correlate with
each other. Therefore, it is difficult to compare cytokine
levels between EBC and induced sputum or BAL fluids. In
a study by Ko et al, EBC IL-8 concentration measured by an
ELISA kit was undetectable in most patients with exacer-
bated COPD.21 The authors suggest that they might miss the
peak of IL-8 at the start of COPD exacerbations, as the EBC
collection was after 5 days of steroids treatment. In our
study, the time of EBC collection in COPD patients was on
Day 1 or Day 2 after hospitalization. The hypothesis of
fluctuating cytokine levels over time may explain the
IL-8 in serum and exhaled breath condensate 913difference in EBC IL-8 detection between our study and the
previous study.
Tobacco smoking has been demonstrated to have
a considerable effect on H2O2, 8-isoprostane, nitrite and
nitrotyrosine concentrations in EBC.22e25 In our study,
healthy participants were all non-smokers, and patients
with exacerbated COPD were all smokers. In patients with
asthma attacks, no difference was observed in the mean
cytokine levels between smokers and non-smokers (data
not presented). This finding is limited for its small size in
the asthma group. By contrast, patients who were smokers
were requested to refrain from smoking for at least 12
hours before EBC collection. Therefore, the influence of
smoking on these cytokine concentrations (IL-8, IL-17, IL-4,
and TNF-a) in EBC needs further study.
Our study also showed that patients with exacerbated
COPD had higher serum IL-8 levels than patients with
asthma attacks. A study by Hollander et al,19 demonstrated
no significant difference in serum IL-8 concentrations
between COPD and asthma patients, although the mean
value was higher in the COPD group. The COPD and asthma
patients in our study had acute exacerbations of their
symptoms, which was different from the stable patients in
the previous study. The amplified inflammation in COPD
exacerbation may explain why we observed a significant
difference in serum IL-8 between asthma and COPD
patients. The inflammation in COPD patients appeared to
extend beyond the lungs and this may play a role in the
systemic effects of the disease and its associated comor-
bidities.26 Patients with COPD were shown to have
increased levels of circulating inflammatory markers, such
as C-reactive protein or TNF-a.27 In our study, an increased
serum IL-8 level in patients with exacerbated COPD
suggests a systemic inflammatory effect in these patients.
However, the regulatory mechanisms of serum IL-8
expression are not clear. It is unknown whether systemic
inflammation is a primary or secondary phenomenon
related to pulmonary inflammation.
The accumulation of neutrophils in airways appears to
be linked to the long-term course and exacerbation of
COPD. Some studies demonstrated that stimulation of
human airway epithelial cells with IL-17 in vitro causes the
release of IL-8.28e30 There is also evidence that pretreat-
ment of the IL-17 protein with a specific neutralizing anti-
body attenuates its effect on IL-8.30 IL-17 appears to recruit
neutrophils via release of chemokines, such as IL-8, from
epithelial cells. Although some patients with asthma were
demonstrated to have an increased IL-17 concentration in
their BAL fluids or EBC,31,32 there is no information on the
expression of IL-17 in COPD. In this study, there was no
significant difference in EBC IL-17 concentrations among
patients with exacerbated COPD, patients with asthma
attacks and healthy individuals. This suggests that IL-17
may not play a causal role in IL-8 induction and the
subsequent mobilization of neutrophils in patients with
exacerbated COPD.
There are some limitations in this study. The relatively
small sample size in each group makes it difficult to draw
a definite and generalized conclusion. Also, age- and sex-
matched control individuals were not enrolled for patients
with exacerbated COPD and asthma attacks, respectively.
Therefore, further studies are required to establish theinfluence of age and sex on EBC biomarkers. In addition,
very low concentrations of cytokines, both in serum and
EBC, were determined by the commercial ELISA kits. Most
of the measured values fell below the validated detection
limits of the relevant ELISAs, and were below the linear
part of the sigmoid calibration curve. Since small variations
in optical density on this portion of the curve can result in
large changes in concentration derived by interpolation, it
is possible that there was some error in the measurement of
low cytokine concentrations. We found no significant
correlation between serum and EBC cytokine levels in each
subgroup of patients. This finding could be affected by the
specific detection limit in the relevant ELISA. Further
analytical methods are emerging to improve the sensitivity
and validity of the measurement of biomarkers in EBC. The
use of cytokine arrays, mass spectrometry, or nuclear
magnetic resonance, should increase the sensitivity of the
assays, and these methods may produce important new
information in the future.7
In conclusion, this study demonstrated that both serum
and EBC IL-8 concentrations were significantly higher in
patients with exacerbated COPD than in patients with
asthma attacks. These results provide evidence that IL-8
might play a more important role in airway and systemic
inflammation in COPD exacerbations than in asthma attacks.Acknowledgments
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